English
简体中文
Total: £ 56.28
Published Date: 2026-03-02 | Pages: 106 | Tables: 102 | Medical Care
The global Metastatic Lung Adenocarcinoma Treatment market was valued at US$ 5101 million in 2025 and is anticipated to reach US$ 10230 million by 2032, at a CAGR of 10.6% from 2026 to 2032.
Metastatic lung adenocarcinoma treatment focuses on managing advanced non-small cell lung cancer (NSCLC) that has spread beyond the lungs to other parts of the body. The treatment approach is typically multidisciplinary and personalized based on the patient’s overall health, cancer characteristics, and genetic mutations.
The North American market for Metastatic Lung Adenocarcinoma Treatment is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Metastatic Lung Adenocarcinoma Treatment is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Metastatic Lung Adenocarcinoma Treatment in Hospitals is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Metastatic Lung Adenocarcinoma Treatment include Pfizer, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Novartis AG, Merck KGaA (EMD Serono), F. Hoffmann-La Roche, GlaxoSmithKline, AbbVie Inc., etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Metastatic Lung Adenocarcinoma Treatment market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Metastatic Lung Adenocarcinoma Treatment. The Metastatic Lung Adenocarcinoma Treatment market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Metastatic Lung Adenocarcinoma Treatment market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Metastatic Lung Adenocarcinoma Treatment manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH
Novartis AG
Merck KGaA (EMD Serono)
F. Hoffmann-La Roche
GlaxoSmithKline
AbbVie Inc.
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Other
Segment by Application
Hospitals
Specialty Clinics
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Metastatic Lung Adenocarcinoma Treatment companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Radiation Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Metastatic Lung Adenocarcinoma Treatment Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metastatic Lung Adenocarcinoma Treatment Market Perspective (2021–2032)
2.2 Global Metastatic Lung Adenocarcinoma Treatment Growth Trends by Region
2.2.1 Global Metastatic Lung Adenocarcinoma Treatment Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Metastatic Lung Adenocarcinoma Treatment Historic Market Size by Region (2021–2026)
2.2.3 Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Region (2027–2032)
2.3 Metastatic Lung Adenocarcinoma Treatment Market Dynamics
2.3.1 Metastatic Lung Adenocarcinoma Treatment Industry Trends
2.3.2 Metastatic Lung Adenocarcinoma Treatment Market Drivers
2.3.3 Metastatic Lung Adenocarcinoma Treatment Market Challenges
2.3.4 Metastatic Lung Adenocarcinoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metastatic Lung Adenocarcinoma Treatment Players by Revenue
3.1.1 Global Top Metastatic Lung Adenocarcinoma Treatment Players by Revenue (2021–2026)
3.1.2 Global Metastatic Lung Adenocarcinoma Treatment Revenue Market Share by Players (2021–2026)
3.2 Global Top Metastatic Lung Adenocarcinoma Treatment Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Metastatic Lung Adenocarcinoma Treatment Revenue
3.4 Global Metastatic Lung Adenocarcinoma Treatment Market Concentration Ratio
3.4.1 Global Metastatic Lung Adenocarcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Lung Adenocarcinoma Treatment Revenue in 2025
3.5 Global Key Players of Metastatic Lung Adenocarcinoma Treatment Head Offices and Areas Served
3.6 Global Key Players of Metastatic Lung Adenocarcinoma Treatment, Products and Applications
3.7 Global Key Players of Metastatic Lung Adenocarcinoma Treatment, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Metastatic Lung Adenocarcinoma Treatment Breakdown Data by Type
4.1 Global Metastatic Lung Adenocarcinoma Treatment Historic Market Size by Type (2021–2026)
4.2 Global Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Type (2027–2032)
5 Metastatic Lung Adenocarcinoma Treatment Breakdown Data by Application
5.1 Global Metastatic Lung Adenocarcinoma Treatment Historic Market Size by Application (2021–2026)
5.2 Global Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Metastatic Lung Adenocarcinoma Treatment Market Size (2021–2032)
6.2 North America Metastatic Lung Adenocarcinoma Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2021–2026)
6.4 North America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metastatic Lung Adenocarcinoma Treatment Market Size (2021–2032)
7.2 Europe Metastatic Lung Adenocarcinoma Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2021–2026)
7.4 Europe Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size (2021–2032)
8.2 Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size by Region (2021–2026)
8.4 Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Metastatic Lung Adenocarcinoma Treatment Market Size (2021–2032)
9.2 Latin America Metastatic Lung Adenocarcinoma Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2021–2026)
9.4 Latin America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size (2021–2032)
10.2 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2021–2026)
10.4 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Metastatic Lung Adenocarcinoma Treatment Introduction
11.1.4 Pfizer Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Metastatic Lung Adenocarcinoma Treatment Introduction
11.2.4 Eli Lilly and Company Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.2.5 Eli Lilly and Company Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Metastatic Lung Adenocarcinoma Treatment Introduction
11.3.4 AstraZeneca Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.3.5 AstraZeneca Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Metastatic Lung Adenocarcinoma Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Details
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Metastatic Lung Adenocarcinoma Treatment Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Metastatic Lung Adenocarcinoma Treatment Introduction
11.6.4 Novartis AG Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.6.5 Novartis AG Recent Development
11.7 Merck KGaA (EMD Serono)
11.7.1 Merck KGaA (EMD Serono) Company Details
11.7.2 Merck KGaA (EMD Serono) Business Overview
11.7.3 Merck KGaA (EMD Serono) Metastatic Lung Adenocarcinoma Treatment Introduction
11.7.4 Merck KGaA (EMD Serono) Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.7.5 Merck KGaA (EMD Serono) Recent Development
11.8 F. Hoffmann-La Roche
11.8.1 F. Hoffmann-La Roche Company Details
11.8.2 F. Hoffmann-La Roche Business Overview
11.8.3 F. Hoffmann-La Roche Metastatic Lung Adenocarcinoma Treatment Introduction
11.8.4 F. Hoffmann-La Roche Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.8.5 F. Hoffmann-La Roche Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Metastatic Lung Adenocarcinoma Treatment Introduction
11.9.4 GlaxoSmithKline Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.9.5 GlaxoSmithKline Recent Development
11.10 AbbVie Inc.
11.10.1 AbbVie Inc. Company Details
11.10.2 AbbVie Inc. Business Overview
11.10.3 AbbVie Inc. Metastatic Lung Adenocarcinoma Treatment Introduction
11.10.4 AbbVie Inc. Revenue in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
11.10.5 AbbVie Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy
Table 5. Key Players of Radiation Therapy
Table 6. Key Players of Other
Table 7. Global Metastatic Lung Adenocarcinoma Treatment Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Metastatic Lung Adenocarcinoma Treatment Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Metastatic Lung Adenocarcinoma Treatment Market Size by Region (US$ Million), 2021–2026
Table 10. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Region (2021–2026)
Table 11. Global Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Region (2027–2032)
Table 13. Metastatic Lung Adenocarcinoma Treatment Market Trends
Table 14. Metastatic Lung Adenocarcinoma Treatment Market Drivers
Table 15. Metastatic Lung Adenocarcinoma Treatment Market Challenges
Table 16. Metastatic Lung Adenocarcinoma Treatment Market Restraints
Table 17. Global Metastatic Lung Adenocarcinoma Treatment Revenue by Players (US$ Million), 2021–2026
Table 18. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Players (2021–2026)
Table 19. Global Top Metastatic Lung Adenocarcinoma Treatment Players by Tier (Tier 1, Tier 2, and Tier 3), based on Metastatic Lung Adenocarcinoma Treatment Revenue, 2025
Table 20. Ranking of Global Top Metastatic Lung Adenocarcinoma Treatment Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Metastatic Lung Adenocarcinoma Treatment Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Metastatic Lung Adenocarcinoma Treatment, Headquarters and Area Served
Table 23. Global Key Players of Metastatic Lung Adenocarcinoma Treatment, Products and Applications
Table 24. Global Key Players of Metastatic Lung Adenocarcinoma Treatment, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Metastatic Lung Adenocarcinoma Treatment Market Size by Type (US$ Million), 2021–2026
Table 27. Global Metastatic Lung Adenocarcinoma Treatment Revenue Market Share by Type (2021–2026)
Table 28. Global Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global Metastatic Lung Adenocarcinoma Treatment Revenue Market Share by Type (2027–2032)
Table 30. Global Metastatic Lung Adenocarcinoma Treatment Market Size by Application (US$ Million), 2021–2026
Table 31. Global Metastatic Lung Adenocarcinoma Treatment Revenue Market Share by Application (2021–2026)
Table 32. Global Metastatic Lung Adenocarcinoma Treatment Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global Metastatic Lung Adenocarcinoma Treatment Revenue Market Share by Application (2027–2032)
Table 34. North America Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2021–2026
Table 36. North America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size by Country (US$ Million), 2027–2032
Table 49. Pfizer Company Details
Table 50. Pfizer Business Overview
Table 51. Pfizer Metastatic Lung Adenocarcinoma Treatment Product
Table 52. Pfizer Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 53. Pfizer Recent Development
Table 54. Eli Lilly and Company Company Details
Table 55. Eli Lilly and Company Business Overview
Table 56. Eli Lilly and Company Metastatic Lung Adenocarcinoma Treatment Product
Table 57. Eli Lilly and Company Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 58. Eli Lilly and Company Recent Development
Table 59. AstraZeneca Company Details
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Metastatic Lung Adenocarcinoma Treatment Product
Table 62. AstraZeneca Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 63. AstraZeneca Recent Development
Table 64. Bristol-Myers Squibb Company Company Details
Table 65. Bristol-Myers Squibb Company Business Overview
Table 66. Bristol-Myers Squibb Company Metastatic Lung Adenocarcinoma Treatment Product
Table 67. Bristol-Myers Squibb Company Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 68. Bristol-Myers Squibb Company Recent Development
Table 69. Boehringer Ingelheim International GmbH Company Details
Table 70. Boehringer Ingelheim International GmbH Business Overview
Table 71. Boehringer Ingelheim International GmbH Metastatic Lung Adenocarcinoma Treatment Product
Table 72. Boehringer Ingelheim International GmbH Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 73. Boehringer Ingelheim International GmbH Recent Development
Table 74. Novartis AG Company Details
Table 75. Novartis AG Business Overview
Table 76. Novartis AG Metastatic Lung Adenocarcinoma Treatment Product
Table 77. Novartis AG Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 78. Novartis AG Recent Development
Table 79. Merck KGaA (EMD Serono) Company Details
Table 80. Merck KGaA (EMD Serono) Business Overview
Table 81. Merck KGaA (EMD Serono) Metastatic Lung Adenocarcinoma Treatment Product
Table 82. Merck KGaA (EMD Serono) Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 83. Merck KGaA (EMD Serono) Recent Development
Table 84. F. Hoffmann-La Roche Company Details
Table 85. F. Hoffmann-La Roche Business Overview
Table 86. F. Hoffmann-La Roche Metastatic Lung Adenocarcinoma Treatment Product
Table 87. F. Hoffmann-La Roche Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 88. F. Hoffmann-La Roche Recent Development
Table 89. GlaxoSmithKline Company Details
Table 90. GlaxoSmithKline Business Overview
Table 91. GlaxoSmithKline Metastatic Lung Adenocarcinoma Treatment Product
Table 92. GlaxoSmithKline Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 93. GlaxoSmithKline Recent Development
Table 94. AbbVie Inc. Company Details
Table 95. AbbVie Inc. Business Overview
Table 96. AbbVie Inc. Metastatic Lung Adenocarcinoma Treatment Product
Table 97. AbbVie Inc. Revenue in Metastatic Lung Adenocarcinoma Treatment Business (US$ Million), 2021–2026
Table 98. AbbVie Inc. Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Metastatic Lung Adenocarcinoma Treatment Picture
Figure 2. Global Metastatic Lung Adenocarcinoma Treatment Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Type: 2025 vs 2032
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Immunotherapy Features
Figure 7. Radiation Therapy Features
Figure 8. Other Features
Figure 9. Global Metastatic Lung Adenocarcinoma Treatment Market Size by Application (US$ Million), 2021–2032
Figure 10. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Application: 2025 vs 2032
Figure 11. Hospitals Case Studies
Figure 12. Specialty Clinics Case Studies
Figure 13. Other Case Studies
Figure 14. Metastatic Lung Adenocarcinoma Treatment Report Years Considered
Figure 15. Global Metastatic Lung Adenocarcinoma Treatment Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Metastatic Lung Adenocarcinoma Treatment Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Region: 2025 vs 2032
Figure 18. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Players in 2025
Figure 19. Global Metastatic Lung Adenocarcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Metastatic Lung Adenocarcinoma Treatment Revenue in 2025
Figure 21. North America Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Metastatic Lung Adenocarcinoma Treatment Market Share by Country (2021–2032)
Figure 23. United States Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Metastatic Lung Adenocarcinoma Treatment Market Share by Country (2021–2032)
Figure 27. Germany Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Share by Region (2021–2032)
Figure 35. China Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Metastatic Lung Adenocarcinoma Treatment Market Share by Country (2021–2032)
Figure 43. Mexico Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Share by Country (2021–2032)
Figure 47. Israel Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Metastatic Lung Adenocarcinoma Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Pfizer Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 51. Eli Lilly and Company Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 52. AstraZeneca Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 53. Bristol-Myers Squibb Company Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 54. Boehringer Ingelheim International GmbH Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 55. Novartis AG Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 56. Merck KGaA (EMD Serono) Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 57. F. Hoffmann-La Roche Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 59. AbbVie Inc. Revenue Growth Rate in Metastatic Lung Adenocarcinoma Treatment Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
